KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Binghe Xu, Shusen Wang, Min Yan, Joohyuk Sohn, Wei Li, Jinhai Tang, Xiaojia Wang, Ying Wang, Seock-Ah Im, Dongdong Jiang, Theresa Valdez, Anandaroop Dasgupta, Yiran Zhang, Yilin Yan, Kimberly M Komatsubara, Wei-Pang Chung, Fei Ma, Ming-Shen Dai

Nat Med 30(12) 3709-3716

PMID39354196
PMCIDPMC11645259
DOI10.1038/s41591-024-03269-z
发表日期2024-10-01
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已完成可用 Figure 的视觉复核,未识别到合格 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:森林图/亚组分析图;Extended Data Fig. 2:生活质量量表图。
摘要

摘要

Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+HER2-) metastatic breast cancer (mBC) in the global TROPiCS-02 study. TROPiCS-02 enrolled few Asian patients. Here we report results of SG in Asian patients with HR+HER2- mBC from the EVER-132-002 study. Patients were randomized to SG (n = 166) or chemotherapy (n = 165). The primary endpoint was met: PFS was improved with SG versus chemotherapy (hazard ratio of 0.67, 95% confidence interval 0.52-0.87; P = 0.0028; median 4.3 versus 4.2 months). OS also improved with SG versus chemotherapy (hazard ratio of 0.64, 95% confidence interval 0.47-0.88; P = 0.0061; median 21.0 versus 15.3 months). The most common grade ≥3 treatment-emergent adverse events were neutropenia, leukopenia and anemia. SG demonstrated significant and clinically meaningful improvement in PFS and OS versus chemotherapy, with a manageable safety profile consistent with prior studies. SG represents a promising treatment option for Asian patients with HR+HER2- mBC (ClinicalTrials.gov identifier no. NCT04639986 ).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1CONSORT diagram. Of 485 patients screened, 154 were not randomized to a treatment group. The remaining 331 patients were randomized to the SG or chemotherapy groups. a Chemotherapy selected at randomization: eribulin ( n = 131), vinorelbine ( n = 13), capecitabine ( n = 11) or gemcitabine ( n = 10). b One patient was randomized to the SG group but was erroneously administered chemotherapy. c Other reasons included clinical deterioration, pregnancy or administrative problems. d Other reasons included clinical deterioration, pregnancy, administrative problems or patient nonadherence/protocol violations.
非 KM Figure
Fig. 2Kaplan–Meier estimates of PFS and OS. a , Kaplan–Meier curve of PFS per BICR in patients treated with SG ( n = 166) versus chemotherapy ( n = 165). b , Kaplan–Meier curve of PFS per INV in patients treated with SG versus chemotherapy. c , Kaplan–Meier curve of OS in patients treated with SG versus chemotherapy. The median PFS and OS were calculated using the Kaplan–Meier method. The HR values were estimated using a stratified Cox proportional-hazards model, and the P values were calculated using a stratified log-rank test. Dashed blue and grey lines indicate median values, and dashed black lines indicate landmark time points. a Stratified log-rank P value. NE, not estimable.
非 KM Figure
Fig. 3Subgroup analysis of PFS. PFS per BICR with SG versus chemotherapy was analyzed across multiple subgroups. The median PFS was calculated using the Kaplan–Meier method, and HR values were estimated using a Cox proportional-hazards model. a HER2-low was defined as IHC score of 1+ or score of 2+ with a negative fluorescence in situ hybridization result; HER2 IHC0 was defined as an IHC score of 0.
非 KM Figure
Extended Data Fig. 1Subgroup analysis of OS. OS with SG versus chemotherapy was analyzed across multiple subgroups. Median OS was calculated using the Kaplan–Meier method, and HR values were estimated using a Cox proportional-hazards model. a HER2-low was defined as IHC score of 1 + , or score of 2+ with negative fluorescence in situ hybridization result; HER2 IHC0 was defined as IHC score of 0.
非 KM Figure
Extended Data Fig. 2EQ-5D-5L questionnaire responses. Patient responses to the EuroQoL EQ-5D-5L questionnaire were descriptively evaluated for patients randomized to SG ( n = 161, 111) or chemotherapy ( n = 157, 121) at baseline and end of treatment in the EQ-5D-5L-evaluable population.
非 KM Figure